Good evening :)
$
₹
C

Cardiol Therapeutics Inc Class A

CRDL

NASDAQ
C

Cardiol Therapeutics Inc Class A

CRDL

NASDAQ
$2.121.62% (-0.03)
$
₹
$2.121.62% (-0.03)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Micro Cap

With a market cap of $253.5M the stock is ranked 4048

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

14.69
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.24
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 5 analysts' reports

Buy
5 analysts
Hold
0 analyst
Sell
0 analyst

Analysts expect a +294.04% price upside over the next year

Current Price$2.12
Target Price$8.55

Company Profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
—
—
P/E Ratio
73.51
73.51
—
—
1Y Return
24.42%
24.42%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
—
—
P/E Ratio
27.25
27.25
—
—
1Y Return
57.12%
57.12%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
—
—
P/E Ratio
—
—
—
—
1Y Return
33.32%
33.32%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
—
—
P/E Ratio
31.85
31.85
—
—
1Y Return
40.67%
40.67%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
—
—
P/E Ratio
20.36
20.36
—
—
1Y Return
49.79%
49.79%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Cardiol Therapeutics Inc Class A -14.69-
AbbVie Inc73.5150.450.36
Amgen Inc27.2520.262.10

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

-9.9
-7.2
-10.8
-8.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue000000000-
Net Income-9.17-4.81-12.72-5.68-8.28-8.35-9.96-7.21-10.84-8.64
Net Profit Margin----------
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Cardiol Therapeutics Inc Class A (CRDL) share price today is $2.12 as of September 4, 2026 at 10:54 PM IST. The stock touched a day high of $2.17 and a day low of $2.12.

  2. Cardiol Therapeutics Inc Class A stock trades on NASDAQ under the ticker symbol CRDL.

  3. Cardiol Therapeutics Inc Class A's market capitalization is $253.5M as of September 4, 2026 at 10:54 PM IST.

  4. Cardiol Therapeutics Inc Class A's price-to-earnings (P/E) ratio is N/A as of September 4, 2026.

  5. Cardiol Therapeutics Inc Class A's price-to-book (P/B) ratio is 14.69 as of September 4, 2026.

  6. Yes, You can buy Cardiol Therapeutics Inc Class A shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Cardiol Therapeutics Inc Class A shares in three steps: 1. Search Cardiol Therapeutics Inc Class A on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Cardiol Therapeutics Inc Class A trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Cardiol Therapeutics Inc Class A (CRDL) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 4.7058 shares at the current price of $2.12.

Loading...